[Disclosure] Samsung Biologics(207940) Raises 2025 Annual Revenue Guidance to KRW 5.8T (Fair Disclosure)

Fact Source: Financial Supervisory Service DART / 2025-07-23

Disclosure Type: Amending Report / Guidance on Corporate Earnings Projection based on Consolidated Financial Statements (Fair Disclosure)

💡 3-Second Summary

Samsung Biologics has revised its consolidated revenue guidance upward for the fiscal year 2025, lifting its annual revenue target from the previous KRW 5.57 trillion to approximately KRW 5.79 trillion, while modifying its expected year-over-year growth range.

📊 1. [Key Disclosure Content & Summary of Financial Figures]

• Company Name: Samsung Biologics Co., Ltd. (207940)
• Amended Document & Initial Filing Date: Guidance on Corporate Earnings Projection based on Consolidated Financial Statements (Fair Disclosure) / January 22, 2025
• Reason for Amendment: Upward revision of revenue guidance
• Core Revisions (Consolidated Earnings Forecast):
  • FY2025 Revenue Guidance (Period: 2025-01-01 ~ 2025-12-31):
    • [Pre-revision] KRW 5.5705T (5,570.5 billion KRW)
    • [Post-revision] KRW 5.7978T (5,797.8 billion KRW)
  • Estimated Revenue Growth Bounds (Year-over-Year):
    • [Pre-revision] Represents the median value within the estimated growth range (+20% to +25% YoY)
    • [Post-revision] Represents the median value within the estimated growth range (+25% to +30% YoY)
• Basis of Projection: Market outlook and business planning
• Historical Projection Accuracy (FY2024 Baseline):
  • 2024 Revenue guidance of KRW 4.3411T versus actual consolidated performance of KRW 4.5473T, recorded a forecast error rate of 4.7% (Operating profit figures were not provided).
• Other Material Information: The stated figures constitute forward-looking statements based on internal business plans, and actual outcomes may deviate depending on changes in the management and market environment.

📈 2. [Expert Insight: What This Disclosure Means for Investors]

This filing functions as an amending report presenting revised internal forward-looking forecasts rather than delivering finalized historical financials. According to the document, along with the adjustment to the annual consolidated revenue target for FY2025, the year-over-year expected revenue growth range has been modified from the initial +20%~+25% to the revised +25%~+30%.

Investors should note that the adjusted target of KRW 5.7978T is calculated based on the median value of the updated growth range. While historical metrics from FY2024 show a difference between guidance and actual results with a forecast error rate of 4.7%, the new projections for 2025 remain subject to potential variations driven by changes in the business environment. Because this disclosure focuses exclusively on top-line revenue projections and does not provide forecasts for operating profit or net income, investors may monitor these targets alongside future quarterly actual performance.

📝 Editor’s Comment (by K-STOCK Editor)

Samsung Biologics has updated its annual revenue roadmap for 2025! The core fact is that the company adjusted its top-line target upward from KRW 5.5705T to KRW 5.7978T. The year-over-year expected revenue growth range has also shifted from the initial +20%~+25% span to the newly updated +25%~+30% bracket. For historical context, the provided FY2024 data notes a forecast error rate of 4.7% between its guidance and realized revenue. Since this disclosure presents top-line forecasting data and excludes profit margin indicators, investors should lock in these updated target parameters and track how they compare against upcoming quarterly actual earnings releases!

📢 Disclaimer & Source Information

Source: This content has been structured and newly generated based on the official data submitted to the Financial Supervisory Service electronic disclosure system (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.